[TOP STORY] The appetite for GLP-1 drugs grows

Loading player...
‘The nature of the beast is yes, these drugs come off patent; the demand is there and someone could produce it more cheaply’, Integral Asset Management’s Keith McLachlan points out.
24 Jan 2025 3AM English South Africa Business News · Business

Other recent episodes

Spur with a taste for dividends

Analysis of Spur’s strong results against a tougher performance from Exxaro and the opportunities that shifting market regimes are creating for active investors.
21 Aug 1AM 19 min